On heels of Loxo buy, Lartruvo setback deals a blow to Lilly's oncology hopes

After patent expirations and other woes, Eli Lilly has been leaning on a stable of new drugs for growth. But after a trial failure for soft tissue sarcoma launch Lartruvo, the drugmaker is stopping promotion for the drug.